Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...
In a recent study published in the journal Nature Biotechnology, researchers in Switzerland used base and prime editing to create and analyze a wide array of variants of the epithelial growth factor ...
Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Familial Lung Cancer" recently published in the JCO. The authors have no ...
Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized ...
In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
While first-line EGFR inhibitors have revolutionized the treatment of mutant lung cancer, the inevitable development of ...
The relation between body mass index, comorbidity, choice of surgery, and prognostic factors in early breast cancer: Data from a nation-wide Danish cohort No significant financial relationships to ...
Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with progressive shortness of breath and about 10 pounds of unintentional weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results